Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic
Albert Garcia‐Romeu, David J. Cox, Kirsten E. Smith, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107849-107849
Open Access | Times Cited: 144

Showing 76-100 of 144 citing articles:

Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review
Mary Ellen Wright, Claire Ginsberg, Abigail M. Parkison, et al.
Journal of Perinatology (2021) Vol. 41, Iss. 6, pp. 1236-1243
Open Access | Times Cited: 15
Kratom exposures among older adults reported to U.S. poison centers, 2014–2019
Janessa M. Graves, Julia A. Dilley, Lucia Terpak, et al.
Journal of the American Geriatrics Society (2021) Vol. 69, Iss. 8, pp. 2176-2184
Closed Access | Times Cited: 15
Report of ventricular fibrillation in a 44-year-old man using kratom
Maaz Sheikh, Navid Ahmed, Himali Gandhi, et al.
BMJ Case Reports (2021) Vol. 14, Iss. 3, pp. e237837-e237837
Open Access | Times Cited: 14
Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors
Lucja Kudla, Ryszard Przewłocki
Pharmacological Reports (2021) Vol. 73, Iss. 4, pp. 1033-1051
Open Access | Times Cited: 14
We Need Better Estimates of Kratom Use Prevalence
Jack E. Henningfield, Oliver Grundmann, Albert Garcia‐Romeu, et al.
American Journal of Preventive Medicine (2021) Vol. 62, Iss. 1, pp. 132-133
Closed Access | Times Cited: 14
Prevalence of Kratom Use and Co-Occurring Substance Use Disorders in the United States
Kevin Y. Xu, Carrie M. Mintz, Jacob T. Borodovsky, et al.
The Primary Care Companion For CNS Disorders (2021) Vol. 23, Iss. 4
Open Access | Times Cited: 13
Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample
Kirsten E. Smith, Jeffrey M. Rogers, Justin C. Strickland
Journal of Psychoactive Drugs (2021) Vol. 54, Iss. 5, pp. 429-439
Open Access | Times Cited: 13
Acute, Sublethal, and Developmental Toxicity of Kratom (Mitragyna speciosa Korth.) Leaf Preparations on Caenorhabditis elegans as an Invertebrate Model for Human Exposure
Samantha Hughes, David van de Klashorst, Charles A. Veltri, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 10, pp. 6294-6294
Open Access | Times Cited: 9
Public Health Implications and Possible Sources of Lead (Pb) as a Contaminant of Poorly Regulated Kratom Products in the United States
Walter C. Prozialeck, Alexandra Fowler, Joshua R. Edwards
Toxics (2022) Vol. 10, Iss. 7, pp. 398-398
Open Access | Times Cited: 9
Global strategy for New Psychoactive Substances: an update
Balasingam Vicknasingam, Suresh Narayanan, Darshan Singh, et al.
Current Opinion in Psychiatry (2020) Vol. 33, Iss. 4, pp. 295-300
Closed Access | Times Cited: 13
Analysis of heavy metals content in commercially available kratom products in Richmond, Virginia
James H. Fleming, Carol M. Babyak, Emanuele Amorim Alves
Forensic Chemistry (2023) Vol. 33, pp. 100474-100474
Closed Access | Times Cited: 4
Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain
Daniel Farkas, Saadet Inan, Laila N. Heydari, et al.
Life Sciences (2023) Vol. 328, pp. 121878-121878
Closed Access | Times Cited: 4
Kratom as a potential substance use disorder harm reduction agent
MeShell Green, Nina Vadiei, Charles A. Veltri, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 1
Kratom Educational Guide

(2024)
Open Access | Times Cited: 1
Dual Anti-Inflammatory Activities of COX-2/5-LOX Driven by Kratom Alkaloid Extracts in Lipopolysaccharide-induced RAW 264.7 Cells
Siti Irma Rahmawati, Dwi Wahyu Indriani, Febby Nurdiya Ningsih, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Beneficial and Adverse Health Effects of Kratom (Mitragyna speciosa): A Critical Review of the Literature
J. Thomas Heywood, S. Smallets, Dennis J. Paustenbach
Food and Chemical Toxicology (2024) Vol. 192, pp. 114913-114913
Closed Access | Times Cited: 1
Controversies in Assessment, Diagnosis, and Treatment of Kratom Use Disorder
Kirsten E. Smith, David H. Epstein, Stephanie T. Weiss
Current Psychiatry Reports (2024) Vol. 26, Iss. 9, pp. 487-496
Open Access | Times Cited: 1
Associations Between Opioid and Kratom Use in the USA: Differences by Race/Ethnicity and Sexual Orientation
Cassidy R. LoParco, Carlton Bone, Carla J. Berg, et al.
Journal of Racial and Ethnic Health Disparities (2024)
Closed Access | Times Cited: 1
Time course of kratom effects via ecological momentary assessment, by product type, dose amount, and assayed alkaloid content
Kirsten E. Smith, Leigh V. Panlilio, Abhisheak Sharma, et al.
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112460-112460
Open Access | Times Cited: 1
Dual anti-inflammatory activities of COX-2/5-LOX driven by kratom alkaloid extracts in lipopolysaccharide-induced RAW 264.7 cells
Siti Irma Rahmawati, Dwi Wahyu Indriani, Febby Nurdiya Ningsih, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Pentylenetetrazol-like stimulus is not produced following naloxone-precipitated mitragynine withdrawal in rats
Illa Syafiqah Johari, Norsyifa Harun, Zarif Mohamed Sofian, et al.
Psychopharmacology (2021) Vol. 238, Iss. 11, pp. 3183-3191
Closed Access | Times Cited: 9
Kratom: Substance of Abuse or Therapeutic Plant?
David A. Gorelick
Psychiatric Clinics of North America (2022) Vol. 45, Iss. 3, pp. 415-430
Closed Access | Times Cited: 6
Kratom-Associated Mixed Cholestatic-Hepatocellular Liver Injury in a Patient With Long COVID: A case Report
Yotsapon Thewjitcharoen, Sirinate Krittiyawong, Soontaree Nakasatien, et al.
Clinical Medicine Insights Case Reports (2022) Vol. 15
Open Access | Times Cited: 6
Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder – a narrative review
Alexandra Arenson, Cynthia I. Campbell, Ilan Remler
Journal of Addictive Diseases (2023) Vol. 42, Iss. 3, pp. 253-263
Closed Access | Times Cited: 3
The effect of mitragynine on extracellular activity of brain dopamine and its metabolites
Nurul H.M. Yusoff, Zurina Hassan, Vikneswaran Murugaiyah, et al.
Brain Research Bulletin (2021) Vol. 178, pp. 1-8
Closed Access | Times Cited: 8

Scroll to top